Alturas Minerals Corp

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1997-01-01

Employees: 2

Market Cap: $476.1M

Website: http://www.altimmune.com

Introduction: Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Clinical Trials

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Phase 2

Recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: Pemvidutide

First Posted Date: 2025-05-23

Last Posted Date: 2025-05-23

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 100

Registration Number: NCT06987513

Locations: 🇺🇸
Altimmune Clinical Study Site, Richmond, Virginia, United States

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)

Phase 2

Active, not recruiting

Conditions: Non-Alcoholic Steatohepatitis (NASH)

Interventions: Drug: Placebo
Drug: Pemvidutide

First Posted Date: 2023-08-14

Last Posted Date: 2024-09-30

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 190

Registration Number: NCT05989711

Locations: 🇵🇷
Altimmune Clinical Study Site, San Juan, Puerto Rico
🇺🇸
Altimmune Clinial Study Site, Tucson, Arizona, United States
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 9 locations

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2

Completed

Conditions: Obesity/Overweight

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2022-03-25

Last Posted Date: 2023-11-29

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 391

Registration Number: NCT05295875

Locations: 🇺🇸
Altimmune CTM, Saint George, Utah, United States
🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
Cornell University, Joan and Sanford Weill Medical College, New York, New York, United States

and more 1 locations

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2022-03-23

Last Posted Date: 2023-07-27

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 64

Registration Number: NCT05292911

Locations: 🇺🇸
Wake Research CRCN, Las Vegas, Nevada, United States
🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Diagnostics Research Group, San Antonio, Texas, United States

and more 8 locations

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2021-11-26

Last Posted Date: 2023-08-14

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 55

Registration Number: NCT05134662

Locations: 🇺🇸
Altimmune CTM, Tomball, Texas, United States

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 1

Completed

Conditions: Non-Alcoholic Fatty Liver Disease

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2021-08-16

Last Posted Date: 2023-07-27

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 95

Registration Number: NCT05006885

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Pinnacle Research, San Antonio, Texas, United States
🇺🇸
Diagnostics Research Group, San Antonio, Texas, United States

and more 10 locations

ALT-801 DDI Study in Healthy Volunteers

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: ALT-801
Drug: Ethinylestradiol and Levonorgestrel
Drug: Metformin
Drug: Warfarin
Drug: Atorvastatin
Drug: Digoxin

First Posted Date: 2021-07-22

Last Posted Date: 2022-12-08

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 40

Registration Number: NCT04972396

Locations: 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Phase 2

Terminated

Conditions: Hepatitis B, Chronic

Interventions: Biological: HepTcell
Drug: Placebo

First Posted Date: 2020-12-28

Last Posted Date: 2024-05-29

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 87

Registration Number: NCT04684914

Locations: 🇬🇧
Queens Medical Center, Nottingham, United Kingdom
🇬🇧
St. Georges University of London, London, United Kingdom
🇪🇸
Hospital Universitario La Paz, Madrid, Spain

and more 18 locations

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: AdCOVID
Other: Placebo

First Posted Date: 2020-12-22

Last Posted Date: 2023-08-14

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 92

Registration Number: NCT04679909

Locations: 🇺🇸
AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸
Clinical Trials of Texas, San Antonio, Texas, United States
🇺🇸
Optimal Research, Austin, Texas, United States

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Phase 1

Completed

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: ALT-801
Other: Placebo

First Posted Date: 2020-09-23

Last Posted Date: 2021-11-10

Lead Sponsor: Altimmune, Inc.

Target Recruit Count: 100

Registration Number: NCT04561245

Locations: 🇦🇺
Nucleus Networks, Herston, Queensland, Australia

Home Terms & Conditions Privacy Policy